Brain cancer vaccine - Northwest Biotherapeutics
Alternative Names: DCVax-Brain; DCVax-Brain personalised immune therapy - Northwest Biotherapeutics; DCVax-L; DCVax-L (Glioblastoma)Latest Information Update: 25 Dec 2023
At a glance
- Originator Northwest Biotherapeutics
- Developer Northwest Biotherapeutics; University of Pennsylvania
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Glioblastoma
- Phase I/II Ovarian cancer
Most Recent Events
- 20 Dec 2023 Preregistration for Glioblastoma (Newly diagnosed) in United Kingdom (Intradermal)
- 20 Dec 2023 Preregistration for Glioblastoma (Recurrent) in United Kingdom (Intradermal)
- 12 Sep 2023 Northwest Biotherapeutics completes phase-I/II clinical trials in Ovarian cancer (Late-stage disease) in USA, prior to September 2023(Intradermal)